Trevi Therapeutics Inc.

Trevi Therapeutics Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for the treatment of serious neurological conditions. The company focuses particularly on central nervous system disorders that have significant unmet medical needs. Its primary product candidate includes an investigational therapy aimed at alleviating the symptoms of chronic pruritus, a severe itching disorder associated with various clinical conditions. Trevi's investigative efforts also explore applications for their therapies in conditions like chronic cough and levodopa induced dyskinesia in Parkinson's disease, highlighting a commitment to enhancing life quality for individuals with these conditions. Operating on a global scale, Trevi Therapeutics Inc. plays a critical role in the biopharmaceutical market by addressing niche yet impactful medical challenges. The company's strategic focus lies in advancing its pipeline through rigorous clinical trials and regulatory pathways, with a vision to offer novel, effective solutions in neurology. Headquartered in New Haven, Connecticut, Trevi leverages its innovative research approach to potentially create new standards in treating persistent neurological symptoms, thereby contributing to broader medical advancements across related healthcare sectors.